Express Scripts excludes Lilly's low cost insulin generic from preferred formulary

Express Scripts Holding Co. (NASDAQ:ESRX) excluded from its 2019 preferred formulary Eli Lilly's newly launched generic insulin product, reinforcing the idea that PBMs want bigger rebates, not cheaper drugs.